Analyst Price Target is $15.00
▲ +67.60% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Co-Diagnostics in the last 3 months. The average price target is $15.00, with a high forecast of $15.00 and a low forecast of $15.00. The average price target represents a 67.60% upside from the last price of $8.95.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in Co-Diagnostics. This Buy consensus rating has held steady for over two years.
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight H. Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.